(MD) Mednax - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58502B1061

MD: Newborn Care, Maternal-Fetal Care, Pediatric Care

Pediatrix Medical Group, Inc. (NYSE: MD), formerly known as MEDNAX, Inc., is a leading provider of specialized pediatric and maternal-fetal healthcare services in the United States. Founded in 1979 and headquartered in Sunrise, Florida, the company operates through its subsidiaries to deliver critical care services across multiple clinical settings. Its core offerings include neonatal care for premature or critically ill newborns, maternal-fetal medicine for high-risk pregnancies, and a range of pediatric subspecialty services. The company employs a multidisciplinary team of neonatologists, pediatric intensivists, maternal-fetal medicine specialists, and other healthcare professionals to provide comprehensive care in hospitals, nurseries, and outpatient clinics. Pediatrix Medical Group also offers newborn hearing screening programs and support services in pediatric emergency rooms, labor and delivery units, and other hospital departments. The companys services are designed to address the complex medical needs of newborns, expectant mothers, and children, leveraging advanced clinical protocols and technology to improve patient outcomes.

From a technical perspective, Pediatrix Medical Groups stock (NYSE: MD) has shown stable price action, with its 20-day moving average at 12.91 closely aligning with its last price of 12.94. The 50-day moving average at 13.88 and 200-day moving average at 12.82 suggest a slight downtrend over the medium term. The average true range (ATR) of 0.59 indicates moderate volatility. On the fundamental side, the companys market cap of $1.1 billion reflects its established presence in the healthcare services sector. The forward P/E of 8.24 points to potential undervaluation, though the negative return on equity (-12.95) raises concerns about profitability. The price-to-book ratio of 1.44 and price-to-sales ratio of 0.55 suggest the stock may offer value for investors willing to overlook short-term financial challenges. Overall, Pediatrix Medical Groups stock is positioned for stability with upside potential, supported by its essential healthcare services and attractive valuations.

Additional Sources for MD Stock

MD Stock Overview

Market Cap in USD 1,110m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Services
IPO / Inception 1995-09-19

MD Stock Ratings

Growth Rating -6.36
Fundamental 4.02
Dividend Rating 0.0
Rel. Strength 77.1
Analysts 3.75/5
Fair Price Momentum 14.79 USD
Fair Price DCF 48.36 USD

MD Dividends

No Dividends Paid

MD Growth Ratios

Growth Correlation 3m -59.5%
Growth Correlation 12m 78.1%
Growth Correlation 5y -75.2%
CAGR 5y 0.45%
CAGR/Max DD 5y 0.01
Sharpe Ratio 12m 0.26
Alpha 62.68
Beta 0.465
Volatility 41.34%
Current Volume 1580.3k
Average Volume 20d 511.9k
What is the price of MD stocks?
As of May 09, 2025, the stock is trading at USD 14.44 with a total of 1,580,307 shares traded.
Over the past week, the price has changed by +13.34%, over one month by +8.82%, over three months by +3.29% and over the past year by +69.88%.
Is Mednax a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Mednax is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 4.02 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MD as of May 2025 is 14.79. This means that MD is currently overvalued and has a potential downside of 2.42%.
Is MD a buy, sell or hold?
Mednax has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MD.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0
What are the forecast for MD stock price target?
According to ValueRays Forecast Model, MD Mednax will be worth about 16 in May 2026. The stock is currently trading at 14.44. This means that the stock has a potential upside of +10.66%.
Issuer Forecast Upside
Wallstreet Target Price 18.1 25.1%
Analysts Target Price 18.1 25.1%
ValueRay Target Price 16 10.7%